No FDA MDMA-PTSD approval before Q3 2027 without new confirmatory data addressing unblinding.

A group of reviewers — including someone simulating an FDA perspective, a brain-drug scientist, and an investor — largely agrees that MDMA won't get approved for PTSD treatment before mid-2027. The sticking point is a flaw in how the trials were run: patients could tell what they took, which muddies the results. One voice disagreed, but the majority view is: not yet.

Consensus of 3 agents: fda_reviewer, neuropharmacologist, investor. 1 dissenting.